Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 and 2 Study of Combination Treatment of Bortezomib, Fludarabine and Cyclophosphamide in Patients With Recurrent Mantle Cell Lymphoma

NCT01322776 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT01322776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01322776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 and 2 Study of Combination Treatment of Bortezomib, Fludarabine and Cyclophosphamide in Patients With Recurrent Mantle Cell Lymphoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 2011
Completion date
October 31, 2013
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma recurrent